Comparative of in-vitro Evaluation between Erlotinib Loaded Nanostructured Lipid Carriers and Liposomes against A549 Lung Cancer Cell Line

Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in gastrointestinal environment, has been considered as a therapeutic agent for Non-Small-Cell Lung Cancer (NSCLC) therapy through oral administration. In the present study, ELT-liposome and ELT-NLCs were...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Iran J Pharm Res
Autores principales: Abedi Gaballu, Fereydoon, Abbaspour-Ravasjani, Soheil, Mansoori, Behzad, Yekta, Reza, Hamishehkar, Hamed, Mohammadi, Ali, Dehghan, Gholamreza, Shokouhi, Behrooz, Ghahremani Dehbokri, Shaho, Baradaran, Behzad
Formato: Artigo
Lenguaje:Inglês
Publicado: Shaheed Beheshti University of Medical Sciences 2019
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6934956/
https://ncbi.nlm.nih.gov/pubmed/32641930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22037/ijpr.2019.1100775
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares